<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308124</url>
  </required_header>
  <id_info>
    <org_study_id>1409066609</org_study_id>
    <nct_id>NCT02308124</nct_id>
  </id_info>
  <brief_title>Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study</brief_title>
  <official_title>Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the effect of treatment of midodrine and pyridostigmine in neurogenic orthostatic
      hypotension and investigate the quality of life of treatment of neurogenic orthostatic
      hypotension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Orthostatic BP Drop</measure>
    <time_frame>after 3-month medical treatment</time_frame>
    <description>Change of orthostatic SBP and DBP drop after 3-month medical treatment compared to initial results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the Orthostatic Hypotension Associated Symptom Questionnaire (OH Questionnaire (OHQ)).</measure>
    <time_frame>after 3-month medical treatment.</time_frame>
    <description>Change of the OH associated symptom survey result after 3-month medical treatment compared to initial results.
OHQ questionnaire has two components: the OH daily activity scale (OHDAS), which contains 4 items measuring the impact of OH on daily activities, and the OH symptom assessment (OHSA), which contains 6 items measuring the symptoms of OH (dizziness/light headedness, vision disturbance, weakness, fatigue, trouble concentrating, and head/neck discomfort).This questionnaire reflects the severity of OH-related symptoms on a 10-point scale, with 0 indicating the absence of a symptom and 10 indicating maximal severity.
** OHQ total score minimal 0 ~ maximal 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the Depression Score (Beck Depression Inventory-II )</measure>
    <time_frame>after 3-month medical treatment.</time_frame>
    <description>Change of the depression score after 3-month medical treatment compared to initial results.
21 multiple-choice questions, each of which can be scored from 0 to 3. Higher score represent higher degree of depression.
Score Normal; 0-13, Mild depression; 14-19, Moderate depression; 20-28, Severe depression; 29-63</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Health-related Quality of Life</measure>
    <time_frame>changes at 3 months after treatment</time_frame>
    <description>changes in Short Form (36) Health Survey version 2 (SF-36v2) physical component summary scale (PCS) compared to the baseline
SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Health-related Quality of Life</measure>
    <time_frame>changes at 3 months after treatment</time_frame>
    <description>changes in Short Form (36) Health Survey version 2 (SF-36v2) mental component summary scale (MCS)
SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Orthostatic; Hypotension, Neurogenic</condition>
  <arm_group>
    <arm_group_label>Midodrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyridostigmine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midodrine + Pyridostigmine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <arm_group_label>Midodrine</arm_group_label>
    <other_name>Midodrine only</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridostigmine Bromide</intervention_name>
    <arm_group_label>Pyridostigmine</arm_group_label>
    <other_name>Pyridostigmine only</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine + pyridostigmine</intervention_name>
    <arm_group_label>Midodrine + Pyridostigmine</arm_group_label>
    <other_name>Combination</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;=18 patients who complained of dizziness

          -  Orthostatic hypotension after 3-minute standing (systolic blood pressure drop &gt;=20 or
             diastolic blood pressure drop &gt;=10

        Exclusion Criteria:

          -  Drug-induced hypotension, if necessary, evaluate patient after discontinuing the
             causative drug for one month

          -  Heart failure or Chronic renal failure

          -  Patients who cannot or do not want to write questionaires.

          -  Poor drug compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Arbique D, Cheek D, Welliver M, Vongpatanasin W. Management of neurogenic orthostatic hypotension. J Am Med Dir Assoc. 2014 Apr;15(4):234-9. doi: 10.1016/j.jamda.2013.10.014. Epub 2014 Jan 2. Review.</citation>
    <PMID>24388946</PMID>
  </reference>
  <reference>
    <citation>Smith ND. Orthostatic Hypotension in the Patient with Diabetes: A Broad Review of Pharmacologic Treatment Options. Journal of Pharmacy Technology. 2013 January 1, 2013;29(1):23-34.</citation>
  </reference>
  <reference>
    <citation>Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 2008 May;7(5):451-8. doi: 10.1016/S1474-4422(08)70088-7. Review.</citation>
    <PMID>18420158</PMID>
  </reference>
  <reference>
    <citation>Shibao C, Grijalva CG, Raj SR, Biaggioni I, Griffin MR. Orthostatic hypotension-related hospitalizations in the United States. Am J Med. 2007 Nov;120(11):975-80.</citation>
    <PMID>17976425</PMID>
  </reference>
  <reference>
    <citation>Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009 Jan 6;119(1):139-46. doi: 10.1161/CIRCULATIONAHA.108.805887. Review.</citation>
    <PMID>19124673</PMID>
  </reference>
  <reference>
    <citation>Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006 Sep;13(9):930-6.</citation>
    <PMID>16930356</PMID>
  </reference>
  <reference>
    <citation>Parsaik AK, Singh B, Altayar O, Mascarenhas SS, Singh SK, Erwin PJ, Murad MH. Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials. J Gen Intern Med. 2013 Nov;28(11):1496-503. doi: 10.1007/s11606-013-2520-3. Epub 2013 Jun 18. Review.</citation>
    <PMID>23775146</PMID>
  </reference>
  <reference>
    <citation>Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, Low PA. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998 Jul;51(1):120-4.</citation>
    <PMID>9674789</PMID>
  </reference>
  <reference>
    <citation>Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012 Apr;22(2):79-90. doi: 10.1007/s10286-011-0146-2. Epub 2011 Nov 2.</citation>
    <PMID>22045363</PMID>
  </reference>
  <reference>
    <citation>Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993 Jul;95(1):38-48.</citation>
    <PMID>7687093</PMID>
  </reference>
  <reference>
    <citation>Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997 Apr 2;277(13):1046-51. Erratum in: JAMA 1997 Aug 6;278(5):388.</citation>
    <PMID>9091692</PMID>
  </reference>
  <reference>
    <citation>Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1294-8.</citation>
    <PMID>12933939</PMID>
  </reference>
  <reference>
    <citation>Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, O'Brien PC, Slezak J, Low PA. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006 Apr;63(4):513-8. Epub 2006 Feb 13.</citation>
    <PMID>16476804</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <results_first_submitted>January 4, 2017</results_first_submitted>
  <results_first_submitted_qc>March 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2017</results_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kon Chu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Midodrine</mesh_term>
    <mesh_term>Pyridostigmine Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Midodrine Only</title>
          <description>Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.</description>
        </group>
        <group group_id="P2">
          <title>Pyridostigmine Only</title>
          <description>Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.</description>
        </group>
        <group group_id="P3">
          <title>Midodrine + Pyridostigmine</title>
          <description>Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Midodrine Only</title>
          <description>Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.</description>
        </group>
        <group group_id="B2">
          <title>Pyridostigmine Only</title>
          <description>Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.</description>
        </group>
        <group group_id="B3">
          <title>Midodrine + Pyridostigmine</title>
          <description>Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="17.7"/>
                    <measurement group_id="B2" value="59.7" spread="13.4"/>
                    <measurement group_id="B3" value="52.7" spread="16.2"/>
                    <measurement group_id="B4" value="57.2" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Supine systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137.3" spread="20.9"/>
                    <measurement group_id="B2" value="124.5" spread="18.5"/>
                    <measurement group_id="B3" value="122.0" spread="15.6"/>
                    <measurement group_id="B4" value="127.9" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Supine diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.2" spread="12.8"/>
                    <measurement group_id="B2" value="76.5" spread="9.8"/>
                    <measurement group_id="B3" value="76.9" spread="10.4"/>
                    <measurement group_id="B4" value="78.9" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Supine heart rate</title>
          <units>Beats per Minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" spread="11.3"/>
                    <measurement group_id="B2" value="66.7" spread="13.5"/>
                    <measurement group_id="B3" value="67.0" spread="10.7"/>
                    <measurement group_id="B4" value="67.2" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Orthostatic systolic blood pressure change</title>
          <description>Maximum decrements in SBP within 3 minutes of standing were recorded.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-24.7" spread="9.9"/>
                    <measurement group_id="B2" value="-23.3" spread="12.5"/>
                    <measurement group_id="B3" value="-22.5" spread="10.1"/>
                    <measurement group_id="B4" value="-23.5" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Orthostatic diastolic blood pressure change</title>
          <description>Maximum decrements in DBP within 3 minutes of standing were recorded.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-13.4" spread="9.0"/>
                    <measurement group_id="B2" value="-15.5" spread="9.9"/>
                    <measurement group_id="B3" value="-13.4" spread="8.2"/>
                    <measurement group_id="B4" value="-14.1" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Orthostatic BP Drop</title>
        <description>Change of orthostatic SBP and DBP drop after 3-month medical treatment compared to initial results.</description>
        <time_frame>after 3-month medical treatment</time_frame>
        <population>At 3 months after treatment, 65 patients were evaluated (Midodrine only; 23, Pyridostigmine only; 21, Midodrine + Pyridostigmine; 21). 22 additional patients missed visit (Midodrine only; 6, Pyridostigmine only; 8, Midodrine + Pyridostigmine; 8)</population>
        <group_list>
          <group group_id="O1">
            <title>Midodrine Only</title>
            <description>Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.</description>
          </group>
          <group group_id="O2">
            <title>Pyridostigmine Only</title>
            <description>Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.</description>
          </group>
          <group group_id="O3">
            <title>Midodrine + Pyridostigmine</title>
            <description>Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Orthostatic BP Drop</title>
          <description>Change of orthostatic SBP and DBP drop after 3-month medical treatment compared to initial results.</description>
          <population>At 3 months after treatment, 65 patients were evaluated (Midodrine only; 23, Pyridostigmine only; 21, Midodrine + Pyridostigmine; 21). 22 additional patients missed visit (Midodrine only; 6, Pyridostigmine only; 8, Midodrine + Pyridostigmine; 8)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes in SBP drop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="16.9"/>
                    <measurement group_id="O2" value="13.6" spread="20.1"/>
                    <measurement group_id="O3" value="8.9" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes in DBP drop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="15.3"/>
                    <measurement group_id="O2" value="11.1" spread="17.7"/>
                    <measurement group_id="O3" value="7.4" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of the Orthostatic Hypotension Associated Symptom Questionnaire (OH Questionnaire (OHQ)).</title>
        <description>Change of the OH associated symptom survey result after 3-month medical treatment compared to initial results.
OHQ questionnaire has two components: the OH daily activity scale (OHDAS), which contains 4 items measuring the impact of OH on daily activities, and the OH symptom assessment (OHSA), which contains 6 items measuring the symptoms of OH (dizziness/light headedness, vision disturbance, weakness, fatigue, trouble concentrating, and head/neck discomfort).This questionnaire reflects the severity of OH-related symptoms on a 10-point scale, with 0 indicating the absence of a symptom and 10 indicating maximal severity.
** OHQ total score minimal 0 ~ maximal 100</description>
        <time_frame>after 3-month medical treatment.</time_frame>
        <population>At 3 months after treatment, 65 patients were evaluated (Midodrine only; 23, Pyridostigmine only; 21, Midodrine + Pyridostigmine; 21). 22 additional patients missed visit (Midodrine only; 6, Pyridostigmine only; 8, Midodrine + Pyridostigmine; 8)</population>
        <group_list>
          <group group_id="O1">
            <title>Midodrine Only</title>
            <description>Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.</description>
          </group>
          <group group_id="O2">
            <title>Pyridostigmine Only</title>
            <description>Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.</description>
          </group>
          <group group_id="O3">
            <title>Midodrine + Pyridostigmine</title>
            <description>Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of the Orthostatic Hypotension Associated Symptom Questionnaire (OH Questionnaire (OHQ)).</title>
          <description>Change of the OH associated symptom survey result after 3-month medical treatment compared to initial results.
OHQ questionnaire has two components: the OH daily activity scale (OHDAS), which contains 4 items measuring the impact of OH on daily activities, and the OH symptom assessment (OHSA), which contains 6 items measuring the symptoms of OH (dizziness/light headedness, vision disturbance, weakness, fatigue, trouble concentrating, and head/neck discomfort).This questionnaire reflects the severity of OH-related symptoms on a 10-point scale, with 0 indicating the absence of a symptom and 10 indicating maximal severity.
** OHQ total score minimal 0 ~ maximal 100</description>
          <population>At 3 months after treatment, 65 patients were evaluated (Midodrine only; 23, Pyridostigmine only; 21, Midodrine + Pyridostigmine; 21). 22 additional patients missed visit (Midodrine only; 6, Pyridostigmine only; 8, Midodrine + Pyridostigmine; 8)</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.2" spread="15.5"/>
                    <measurement group_id="O2" value="-17.2" spread="20.3"/>
                    <measurement group_id="O3" value="-12.6" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of the Depression Score (Beck Depression Inventory-II )</title>
        <description>Change of the depression score after 3-month medical treatment compared to initial results.
21 multiple-choice questions, each of which can be scored from 0 to 3. Higher score represent higher degree of depression.
Score Normal; 0-13, Mild depression; 14-19, Moderate depression; 20-28, Severe depression; 29-63</description>
        <time_frame>after 3-month medical treatment.</time_frame>
        <population>At 3 months after treatment, 65 patients were evaluated (Midodrine only; 23, Pyridostigmine only; 21, Midodrine + Pyridostigmine; 21). 22 additional patients missed visit (Midodrine only; 6, Pyridostigmine only; 8, Midodrine + Pyridostigmine; 8)</population>
        <group_list>
          <group group_id="O1">
            <title>Midodrine Only</title>
            <description>Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.</description>
          </group>
          <group group_id="O2">
            <title>Pyridostigmine Only</title>
            <description>Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.</description>
          </group>
          <group group_id="O3">
            <title>Midodrine + Pyridostigmine</title>
            <description>Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of the Depression Score (Beck Depression Inventory-II )</title>
          <description>Change of the depression score after 3-month medical treatment compared to initial results.
21 multiple-choice questions, each of which can be scored from 0 to 3. Higher score represent higher degree of depression.
Score Normal; 0-13, Mild depression; 14-19, Moderate depression; 20-28, Severe depression; 29-63</description>
          <population>At 3 months after treatment, 65 patients were evaluated (Midodrine only; 23, Pyridostigmine only; 21, Midodrine + Pyridostigmine; 21). 22 additional patients missed visit (Midodrine only; 6, Pyridostigmine only; 8, Midodrine + Pyridostigmine; 8)</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="5.6"/>
                    <measurement group_id="O2" value="-7.8" spread="6.5"/>
                    <measurement group_id="O3" value="-3.5" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Health-related Quality of Life</title>
        <description>changes in Short Form (36) Health Survey version 2 (SF-36v2) physical component summary scale (PCS) compared to the baseline
SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores.</description>
        <time_frame>changes at 3 months after treatment</time_frame>
        <population>At 3 months after treatment, 65 patients were evaluated (Midodrine only; 23, Pyridostigmine only; 21, Midodrine + Pyridostigmine; 21). 22 additional patients missed visit (Midodrine only; 6, Pyridostigmine only; 8, Midodrine + Pyridostigmine; 8)</population>
        <group_list>
          <group group_id="O1">
            <title>Midodrine Only</title>
            <description>Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.</description>
          </group>
          <group group_id="O2">
            <title>Pyridostigmine Only</title>
            <description>Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.</description>
          </group>
          <group group_id="O3">
            <title>Midodrine + Pyridostigmine</title>
            <description>Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Health-related Quality of Life</title>
          <description>changes in Short Form (36) Health Survey version 2 (SF-36v2) physical component summary scale (PCS) compared to the baseline
SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores.</description>
          <population>At 3 months after treatment, 65 patients were evaluated (Midodrine only; 23, Pyridostigmine only; 21, Midodrine + Pyridostigmine; 21). 22 additional patients missed visit (Midodrine only; 6, Pyridostigmine only; 8, Midodrine + Pyridostigmine; 8)</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="6.8"/>
                    <measurement group_id="O2" value="4.2" spread="9.1"/>
                    <measurement group_id="O3" value="2.7" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Health-related Quality of Life</title>
        <description>changes in Short Form (36) Health Survey version 2 (SF-36v2) mental component summary scale (MCS)
SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores.</description>
        <time_frame>changes at 3 months after treatment</time_frame>
        <population>At 3 months after treatment, 65 patients were evaluated (Midodrine only; 23, Pyridostigmine only; 21, Midodrine + Pyridostigmine; 21). 22 additional patients missed visit (Midodrine only; 6, Pyridostigmine only; 8, Midodrine + Pyridostigmine; 8)</population>
        <group_list>
          <group group_id="O1">
            <title>Midodrine Only</title>
            <description>Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.</description>
          </group>
          <group group_id="O2">
            <title>Pyridostigmine Only</title>
            <description>Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.</description>
          </group>
          <group group_id="O3">
            <title>Midodrine + Pyridostigmine</title>
            <description>Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Health-related Quality of Life</title>
          <description>changes in Short Form (36) Health Survey version 2 (SF-36v2) mental component summary scale (MCS)
SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores.</description>
          <population>At 3 months after treatment, 65 patients were evaluated (Midodrine only; 23, Pyridostigmine only; 21, Midodrine + Pyridostigmine; 21). 22 additional patients missed visit (Midodrine only; 6, Pyridostigmine only; 8, Midodrine + Pyridostigmine; 8)</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="8.6"/>
                    <measurement group_id="O2" value="6.7" spread="8.9"/>
                    <measurement group_id="O3" value="0.4" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Possible side effects were checked by direct questioning at each visit at 1 and 3 months after treatment. Expected adverse reactions were listed in the protocol.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Midodrine Only</title>
          <description>Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.</description>
        </group>
        <group group_id="E2">
          <title>Pyridostigmine Only</title>
          <description>Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.</description>
        </group>
        <group group_id="E3">
          <title>Midodrine + Pyridostigmine</title>
          <description>Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study lacked a placebo group and a blinding process Compared with previous studies, which focused on primary autonomic degenerative disorders, our study included more patients with peripheral autonomic neuropathy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jung-Ick Byun</name_or_title>
      <organization>SNUH</organization>
      <phone>+8224406254</phone>
      <email>mr830611@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

